key: cord-0797043-6i3pz4h1
authors: Pineton de Chambrun, Marc; Moyon, Quentin; Faguer, Stanislas; Urbanski, Geoffrey; Mathian, Alexis; Zucman, Noémie; Werner, Marie; Luyt, Charles-Edouard; Verlicchi, Franco; Amoura, Zahir
title: The Consequences Of COVID-19 Pandemic On Patients With Monoclonal Gammopathy Associated Systemic Capillary-Leak Syndrome (Clarkson’s disease)
date: 2021-12-07
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.11.023
sha: 975775ff3a644f73402c3ad0b81760f087c6625a
doc_id: 797043
cord_uid: 6i3pz4h1

nan

presence of a monoclonal gammopathy. Viral infections, especially influenza virus, are known to 3 reveal the disease and to elicit its recurrence [1] [2] [3] . Patients are asymptomatic between episodes. 4

Monoclonal gammopathy of undetermined significance occurs in 3.2% of persons 50 years of age or 5 older and in 5.3% of those 70 years of age or older 4 . However, the incidence and prevalence of 6

Clarkson's disease in this population is unknown, certainly very low 1 . The prevention of severe 7 episodes rely on chronic perfusion of high-dose intravenous immunoglobulins (IVIg) 5 . Aside IVIg and a 8 modest effect of terbutaline, no other treatment have shown to prevent recurrence. Moreover, 9 despite some promising drugs, none have been proven effective in reducing capillary-leak during 10 severe episodes. Several pathophysiological pathways, such as phosphodiesterase inhibition, are 11 candidate for the treatment of severe episodes. 12

The coronavirus disease 2019 (COVID-19) and its preventive vaccines have been recently 13 reported to trigger Clarkson's disease first episodes and relapses 6,7 . We aimed to describe the 14 outcome of European patients with Clarkson's disease from the EurêClark Registry during the COVID-15 19 pandemic. All patients with a diagnosis of monoclonal gammopathy-associated SCLS included in 16 the EurêClark Registry and alive at the start of COVID-19 pandemic (February 1 st 2020), were included 17 and evaluated until July 10 th 2021 ( Table 1) . Thirty patients were included, with a female-to-male 18 ratio 1.3 and a mean±SD age 58±14 years. Every patient had an IgG gammopathy with kappa (n=24) 19 or lambda light chain (n=7). Most patients were under long-term treatment with intravenous 20 immunoglobulins (n=27, 90%). Five patients (17%) experienced a relapse related to a proven (n=3) or 21 highly probable (see Table 1 footnotes) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-22

2) infection, with a fatal outcome in 4 patients. None had evidence of COVID-19 pneumonia and all 23 experienced typical flare of Clarkson's disease with severe hypovolemic shock and refractory multiple 24 organ failure. Twenty patients underwent COVID-19 vaccination with: BNT162b2 (Pfizer-BioNTech) had a new diagnosis Clarkson's disease and were reported to the EurêClark Registry ( Table 2) . All 3 required intensive care unit management, and one died during this opening episode. Four had their 4 first flare triggered by a PCR-confirmed COVID-19 infection. The last patient, previously known to 5 have a monoclonal gammopathy, had a typical opening flare of SCLS 3 days after the first injection of 6 ChAdOx1 (AstraZeneca). 7

Our results highlight the burden of COVID-19 pandemic for patients with Clarkson's disease. 8

They face the threat of both the infection and its preventive vaccine. Moreover, IVIg seems to 9 protect them imperfectly against these foes. Several lessons can be drawn from our results jointly 10 with previous reports. First, COVID-19 infection seems to induce very frequently a relapse of 11

Clarkson's. Every patient from our cohort with a proven or suspected SARS-CoV-2 infection had a 12 severe flare, fatal in 80% of cases. To the best of our knowledge and in the published literature, there 13 are no report of uneventful SARS-CoV-2 infection in these patients. As previously reported, viral 14 infection frequently elicit relapse in Clarkson's disease patients. However, vascular leakage seems to 15 play a major role in COVID-19 pathophysiology and may explain the high relapse risk during SARS-16

CoV-2 infection. While IVIg have been shown to prevent severe episodes 8 and to improve survival 5 , 17 they failed to prevent the COVID-19-related relapses in 4 of our patients, including one treated at full 18 dose (2g/kg/4 weeks). The tapered dose in the 3 others might have lowered their preventive effect. 19

The lack of SARS-CoV-2 specific immunoglobulins in available preparations of IVIg could explain this 20 lower efficacy 6 . A recent study revealed the apparition of anti-SARS-CoV-2 NP and S-RBD antibodies 21 in IVIg preparation containing plasma collected in Italy after March 2020 9 . Yet, it cannot be denied 22 that some patients from our cohort might have had asymptomatic COVID-19 during the time of the 23 study. Second, while the incidence of Clarkson's disease is unknown, being probably very low, this 24 pandemic has been associated with an elevated number of new diagnosis in a short period of time. 25 recommended vaccination in our patients (especially against influenzae virus), COVID-19 vaccines 1 have been shown to trigger Clarkson's disease episodes. All four vaccines authorised by the European 2 Medicines Agency (EMA, BNT162b2, Ad26.COV2.S, mRNA-1273 and ChAdOx1) have be incriminated 3 and not solely the ChAdOx1 (AstraZeneca) for which this adverse effect was recently pointed out by 4 the EMA's safety committee. Conversely with cases reported by Kirk M. Druey's team 7 , our 2 patients 5 relapsing after vaccination were given IVIg regularly. Furthermore, 18 patients, including 2 not 6 receiving IVIg had no adverse event after COVID-19 vaccination. 7

This study has several strength and limitations. First, the small sample size of this series 8 should be put in perspective with the rarity of the disease. Second, while the retrospective nature of 9 this work is inevitably associated with selection bias, most informations originate from prospectively 10 collected data. Third, only symptomatic episodes after vaccination were monitored but not any other 11 vaccine adverse reactions. Last, we did not evaluate the anti-spike antibody response to confirm that 12 

Idiopathic systemic capillary leak syndrome (Clarkson disease)

Monoclonal gammopathy could not be found during the acute episode and will be tested few weeks/month after the flare 5 Monoclonal gammopathy could not be found during the acute episode and the patient died